Abstract
Apoptosis is involved in the action of several (and perhaps all) cancer-chemotherapeutic agents. Prodigiosins, a family of natural red pigments characterized by a common pyrrolylpyrromethene skeleton, are produced by various bacteria. Three members of the prodigiosin family, viz. prodigiosin (PG), undecylprodigiosin (UP) and cycloprodigiosin hydrochloride (cPrG HCl), have immunosuppressive properties and apoptotic effects on cancer cells in vitro and in vivo. Their cytotoxic effect is attributed to the presence of the C-6 methoxy substituent. The A-pyrrole ring plays a key role in both the copper nuclease activity and the cytotoxicity of prodigiosins. Here, we have reviewed the pharmacological activity of PG and related compounds, including novel synthetic PG-derivatives with lower toxicity. The mechanism of action for these molecules is a current topic in biomedicine. The molecular targets of prodigiosins are also discussed.
Keywords: prodigiosin, anticancer drug, prodigiosin family, pg, undecylprodigiosin
Current Cancer Drug Targets
Title: The Prodigiosins: A New Family of Anticancer Drugs
Volume: 3 Issue: 1
Author(s): Beatriz Montaner and Ricardo Pérez-Tomás
Affiliation:
Keywords: prodigiosin, anticancer drug, prodigiosin family, pg, undecylprodigiosin
Abstract: Apoptosis is involved in the action of several (and perhaps all) cancer-chemotherapeutic agents. Prodigiosins, a family of natural red pigments characterized by a common pyrrolylpyrromethene skeleton, are produced by various bacteria. Three members of the prodigiosin family, viz. prodigiosin (PG), undecylprodigiosin (UP) and cycloprodigiosin hydrochloride (cPrG HCl), have immunosuppressive properties and apoptotic effects on cancer cells in vitro and in vivo. Their cytotoxic effect is attributed to the presence of the C-6 methoxy substituent. The A-pyrrole ring plays a key role in both the copper nuclease activity and the cytotoxicity of prodigiosins. Here, we have reviewed the pharmacological activity of PG and related compounds, including novel synthetic PG-derivatives with lower toxicity. The mechanism of action for these molecules is a current topic in biomedicine. The molecular targets of prodigiosins are also discussed.
Export Options
About this article
Cite this article as:
Montaner Beatriz and Pérez-Tomás Ricardo, The Prodigiosins: A New Family of Anticancer Drugs, Current Cancer Drug Targets 2003; 3 (1) . https://dx.doi.org/10.2174/1568009033333772
DOI https://dx.doi.org/10.2174/1568009033333772 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atomistic Insights Into the Regulatory Mechanisms Mediated by Post- Translational Modifications: Molecular Dynamics Investigations
Current Physical Chemistry Bioinformatics Approach for Data Capturing: The Case of Breast Cancer
Current Cancer Therapy Reviews Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation
Current Stem Cell Research & Therapy iNOS: A Potential Therapeutic Target for Malignant Glioma
Current Molecular Medicine L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine Natural Products Targeting Cancer Stem Cells: A Revisit
Current Medicinal Chemistry Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Viral Origins of Human Cancer
Current Medicinal Chemistry Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Clinical Applicability of Microarray Technology in the Diagnosis, Prognostic Stratification, Treatment and Clinical Surveillance of Cervical Adenocarcinoma
Current Pharmaceutical Design Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy The Role of DNA-Microarray in Translational Cancer Research
Current Pharmacogenomics New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets Vascular Endothelial Growth Factor and Diabetic Retinopathy: Role of Oxidative Stress
Current Drug Targets Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Tobacco, Inflammation, and Respiratory Tract Cancer
Current Pharmaceutical Design